Long term inhibition of complement C1s in patients with cold agglutinin disease: results from a named patient program

被引：0
|
作者：
Jilma, B. [1 ]
Gelbenegger, G. [1 ]
Derhaschnig, U. [1 ]
Sillaber, C. [2 ]
D'Sa, S. [3 ]
Fillitz, M. [4 ]
Schenk, T. [5 ]
Gilbert, J. [6 ]
Cartwright, R. [7 ]
Jaeger, U. [2 ]
机构：
[1] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 1, Div Hematol, Vienna, Austria
[3] Univ Coll London Hosp NHS Fdn Trust, UCLH Ctr Waldenstroms Macroglobulinaemia & Relate, London, England
[4] Hanusch Hosp, Dept Internal Med, Vienna, Austria
[5] Univ Klinikum St Polten, Dept Internal Med, St Polten, Austria
[6] Band Therapeut, Lexington, MA USA
[7] Worthing Hosp Western Sussex Hosp, Worthing, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V46
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [41] Classical Pathway of Complement Activation in ITP: Inhibition By TNT003, a Novel C1s Inhibitor
    Peerschke, Ellinor I. B.
    Panicker, Sandip
    Sughroue, Alexa M.
    Bussel, James B.
    [J]. BLOOD, 2014, 124 (21)
  • [42] Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
    Roeth, Alexander
    Barcellini, Wilma
    Tvedt, Tor Henrik Anderson
    Miyakawa, Yoshitaka
    Kuter, David J.
    Su, Jun
    Jiang, Xiaoyu
    Hobbs, William
    Arias, Jaime Morales
    Shafer, Frank
    Weitz, Ilene C.
    [J]. ANNALS OF HEMATOLOGY, 2022, 101 (10) : 2169 - 2177
  • [43] Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study
    Alexander Röth
    Wilma Barcellini
    Tor Henrik Anderson Tvedt
    Yoshitaka Miyakawa
    David J. Kuter
    Jun Su
    Xiaoyu Jiang
    William Hobbs
    Jaime Morales Arias
    Frank Shafer
    Ilene C. Weitz
    [J]. Annals of Hematology, 2022, 101 : 2169 - 2177
  • [44] TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins
    Shi, Ju
    Rose, Eileen L.
    Singh, Andrew
    Hussain, Sami
    Stagliano, Nancy E.
    Parry, Graham C.
    Panicker, Sandip
    [J]. BLOOD, 2014, 123 (26) : 4015 - 4022
  • [45] Outer surface lipoproteins from the Lyme disease spirochete exploit the molecular switch mechanism of the complement protease C1s
    Garrigues, Ryan J.
    Thomas, Sheila
    Leong, John M.
    Garcia, Brandon L.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (11)
  • [46] DECADE Trial: Inhibition of theterminal complement system using the anti-C5 antibody eculizumab for the treatment of cold agglutinin disease (CAD)
    Roeth, A.
    Huettmann, A.
    Duehrsen, U.
    [J]. ONKOLOGIE, 2010, 33 : 112 - 112
  • [47] Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity
    Colonna, Lucrezia
    Parry, Graham C.
    Panicker, Sandip
    Elkon, Keith B.
    [J]. CLINICAL IMMUNOLOGY, 2016, 163 : 84 - 90
  • [48] Molecular features and the transcriptional and functional delineation of complement system activators C1r and C1s from Sebastes schlegelii
    Nilojan, Jehanathan
    Bathige, S. D. N. K.
    Kugapreethan, Roopasingam
    Yang, Hyerim
    Kim, Myoung-Jin
    Nam, Bo-Hye
    Lee, Jehee
    [J]. DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY, 2018, 81 : 279 - 290
  • [49] C1s inhibition by BIVV009 prevents complement-enhanced activation of autoimmune human B cells in vitro
    Nikitin, Pavel A.
    Rose, Eileen L.
    Byun, Tony S.
    Parry, Graham C.
    Panicker, Sandip
    [J]. MOLECULAR IMMUNOLOGY, 2018, 102 : 193 - 193
  • [50] An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database
    Pham, Huy P.
    Wilson, Amanda
    Adeyemi, Ayoade
    Miles, Gandarvaka
    Kuang, Kammy
    Carita, Paulo
    Joly, Florence
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (12): : 1419 - 1428
12345